SCHEMBL2365716

SCHEMBL2365716

COc1cc(N2CCOC2=O)ccc1C(=O)N1CCN(c2ccc(C)cc2C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.54
HTT P42858 6/20 0.54
TP53 P04637 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 4/20 0.48
ALDH1A1 P00352 4/20 0.48
TSHR P16473 1/20 0.48
HPGD P15428 1/20 0.48
POLB P06746 1/20 0.47
GFER P55789 3/20 0.45
MAPK1 P28482 1/20 0.45
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366359 0.89 LMNA (0.53) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2365669 0.87 LMNA (0.61) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2365771 0.87 LMNA (0.51) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL15005826 0.86 LMNA (0.49) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2366120 0.84 LMNA (0.48) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2366313 0.84 LMNA (0.48) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2366377 0.83 HTT (0.62) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2365904 0.81 LMNA (0.45) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL2365973 0.80 HTT (0.57) LMNAHTTTP53SMN1; SMN2MEN1
SCHEMBL12240550 0.79 LMNA (0.52) LMNAHTTTP53SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 LMNA 3668/4885HTT 1580/4885TP53 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.